» Articles » PMID: 35705880

Mechanisms That Regulate the Activities of TET Proteins

Overview
Publisher Springer
Specialty Biology
Date 2022 Jun 15
PMID 35705880
Authors
Affiliations
Soon will be listed here.
Abstract

The ten-eleven translocation (TET) family of dioxygenases consists of three members, TET1, TET2, and TET3. All three TET enzymes have Fe and α-ketoglutarate (α-KG)-dependent dioxygenase activities, catalyzing the 1st step of DNA demethylation by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), and further oxidize 5hmC to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Gene knockout studies demonstrated that all three TET proteins are involved in the regulation of fetal organ generation during embryonic development and normal tissue generation postnatally. TET proteins play such roles by regulating the expression of key differentiation and fate-determining genes via (1) enzymatic activity-dependent DNA methylation of the promoters and enhancers of target genes; and (2) enzymatic activity-independent regulation of histone modification. Interacting partner proteins and post-translational regulatory mechanisms regulate the activities of TET proteins. Mutations and dysregulation of TET proteins are involved in the pathogenesis of human diseases, specifically cancers. Here, we summarize the research on the interaction partners and post-translational modifications of TET proteins. We also discuss the molecular mechanisms by which these partner proteins and modifications regulate TET functioning and target gene expression. Such information will help in the design of medications useful for targeted therapy of TET-mutant-related diseases.

Citing Articles

Epigenetic regulation-mediated disorders in dopamine transporter endocytosis: A novel mechanism for the pathogenesis of Parkinson's disease.

Liang Z, Liu W, Cao M, Cui J, Lan J, Ding Y Theranostics. 2025; 15(6):2250-2278.

PMID: 39990232 PMC: 11840736. DOI: 10.7150/thno.107436.


Novel Epigenetics Control (EpC) Nanocarrier for Cancer Therapy Through Dual-Targeting Approach to DNA Methyltransferase and Ten-Eleven Translocation Enzymes.

Mitsuhashi R, Sato K, Kawakami H Epigenomes. 2025; 9(1).

PMID: 39982248 PMC: 11843842. DOI: 10.3390/epigenomes9010006.


ROS-regulated SUR1-TRPM4 drives persistent activation of NLRP3 inflammasome in microglia after whole-brain radiation.

Chang Y, He Y, Wang D, Zhang K, Zhang Y, Li Z Acta Neuropathol Commun. 2025; 13(1):16.

PMID: 39871308 PMC: 11771008. DOI: 10.1186/s40478-025-01932-1.


miR-143-3p/TET1 Axis Regulates GPC1 Through DNA Methylation and Impairs the Malignant Biological Behaviour of HCC via the Hippo Signalling Pathway.

Liu Y, Du D, Gu X, He Q, Xiong B J Cell Mol Med. 2025; 29(2):e70282.

PMID: 39823268 PMC: 11740985. DOI: 10.1111/jcmm.70282.


Vitamin C and MEK Inhibitor PD0325901 Synergistically Promote Oligodendrocytes Generation by Promoting DNA Demethylation.

Ren X, Yang Y, Wang M, Yuan Q, Suo N, Xie X Molecules. 2025; 29(24.

PMID: 39770028 PMC: 11677943. DOI: 10.3390/molecules29245939.


References
1.
Maiti A, Drohat A . Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem. 2011; 286(41):35334-35338. PMC: 3195571. DOI: 10.1074/jbc.C111.284620. View

2.
Smith A, Mohamedali A, Kulasekararaj A, Lim Z, Gaken J, Lea N . Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010; 116(19):3923-32. DOI: 10.1182/blood-2010-03-274704. View

3.
Mancini M, Veljkovic N, Leo E, Aluigi M, Borsi E, Galloni C . Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia. J Cell Biochem. 2012; 113(8):2765-74. DOI: 10.1002/jcb.24154. View

4.
Yao W, Wu F, Zhang W, Chuang S, Thompson J, Chen Z . Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. J Pathol. 2019; 250(3):346-357. PMC: 7064999. DOI: 10.1002/path.5376. View

5.
Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M . Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009; 114(1):144-7. PMC: 2710942. DOI: 10.1182/blood-2009-03-210039. View